Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORTIFY: NG-350A plus pembrolizumab in metastatic or advanced epithelial tumours
2023-503457-35-00Phase 2Completed
- Sponsor
- Akamis Bio
- Start
- Jun 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Oncolytic Viruses → Oncolytic Therapeutics
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of NG-350A and pembrolizumab in glandular neoplasm and metastasis, sponsored by Akamis Bio. Primary endpoints: Incidence of adverse events and Dose-limiting toxicities. Started Jun 2023; status: completed.
02
Drugs
NG-350Apembrolizumab
03
Conditions
glandular neoplasmmetastasis
Beyond the preview
Go deeper on 2023-503457-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503457-35-00.